Naxitamab-gqgk – Uses, Dosage, Side Effects, Interaction Naxitamab is a GD2-targeted IgG1 monoclonal antibody for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow. Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[rx,rx] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neuroblastoma – it is widely expressed across and within neuroblastomas (and other neuroectodermal tumors),[rx] and is rarely subject to antigen loss.[rx] The first anti-GD2-monoclonal IgG antibody to be approved by the FDA for the treatment of neuroblastoma was dinutuximab under the brand name Unituxin in 2015.[rx] One stark disadvantage of this therapy is the requirement for concurrent use of granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA).[rx] Naxitamab-gqgk (Danyelza) was granted accelerated approval by the FDA in November 2020 for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow.[rx] This approval requires naxitamab to be co-administered only with GM-CSF, a factor known to enhance the granulocyte-mediated antibody-dependent cytotoxicity of anti-GD2 therapies,[rx] making the administration of naxitamab therapy markedly simpler than that of its predecessor. Mechanism of action Neuroblastomas are neuroendocrine tumors occurring in immature and developing cells of the nervous system and are the most common malignancy diagnosed in children <1 year of age.[rx] The GD2 disialoganglioside is a glycolipid found highly expressed on the surface of neuroectodermal tumors,[rx] including neuroblastomas. GD2 exhibits high density and homogeneity across neuroblastomas and a rare occurrence of antigen loss,[rx] making it a desirable target in the treatment of these cancers. Naxitamab is an IgG1 monoclonal antibody directed against GD2 disialogangliosides – it binds to GD2 on the surface of neuroblastoma cells and induces both complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC),[rx] the latter of which is enhanced by co-administration with GM-CSF.[rx] or In targeting cell surface glycoproteins (GD2) that occur on the surface of neuroendocrine tumors, naxitamab directs the immune system toward these cancerous cells and induces the activation of both complement-dependent and antibody-dependent cytotoxicity.[rx] Naxitamab can cause serious infusion reactions – including hypotension, hypoxia, anaphylaxis, and cardiac arrest – that necessitate careful monitoring during therapy. All patients should be pre-medicated with intravenous corticosteroids (e.g. methylprednisolone) as well as an antihistamine, H2 receptor antagonist, acetaminophen, and an antiemetic prior to therapy to mitigate the risk and severity of infusion-related reactions. Naxitamab may also cause severe neurotoxicity, including significant neuropathic pain, transverse myelitis, reversible posterior leukoencephalopathy syndrome (RPLS), and ocular toxicities. Pain management should be implemented prior to and during therapy – patients should take a 12-day course of neuropathic pain prophylaxis (e.g. gabapentin) starting 4 days prior to infusion and should receive oral opioids 45-60 minutes prior to infusion and intravenous opioids and/or ketamine as needed thereafter.[rx] Indications Naxitamab-gqgk is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of patients 1 year of age and older with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.[rx] High-risk, refractory Neuroblastomas of the bone or bone marrow High-risk, relapsed Neuroblastomas of the bone or bone marrow In combination with granulocyte-macrophage colony-stimulating factor (GMCSF) for relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. Use in Cancer Naxitamab-gqgk is approved to be used with granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat: Neuroblastoma in the bone or bone marrow that is high risk and has relapsed (come back) or is refractory (does not respond to treatment). It is used in children aged 1 year and older and adults who had at least a partial response to other types of treatment. This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that naxitamab-gqgk provides a clinical benefit in these patients. Contraindications inflammation of the spinal cord a painful condition that affects the nerves in the legs and arms called peripheral neuropathy a decrease in sharpness of vision called reduced visual acuity high blood pressure an inability to completely empty the bladder pregnancy a patient who is producing milk and breastfeeding a type of brain disorder called posterior reversible encephalopathy syndrome Dosage Strengths: gqgk 4 mg/mL Neuroblastoma 3 mg/kg/day (up to 150 mg/day) IV on Days 1, 3, and 5 of each cycle in combination with GM-CSF subcutaneously NOTE: For the first infusion (Cycle 1, Day 1), administer over 60 minutes; for subsequent infusions, administered over 30 to 60 minutes, as tolerated. RECOMMENDED DOSE REGIMEN FOR EACH TREATMENT CYCLE: DAYS -4 to 0: Administer GM-CSF 250 mcg/m2 subcutaneously daily beginning 5 days prior to naxitamab infusion DAYS 1 to 5: Administer GM-CSF 500 mcg/m2 subcutaneously daily at least 1 hour prior to naxitamab on Days 1, 3, and 5 DAYS 1, 3, and 5: Administer naxitamab 3 mg/kg/day (up to 150 mg/day) IV Duration of therapy: Cycles are repeated every 4 weeks until complete response or partial response, followed by 5 additional cycles every 4 weeks. Subsequent cycles may be repeated every 8 weeks. Discontinue this drug and GM-CSF for disease progression or unacceptable toxicity. PREMEDICATIONS AND SUPPORTIVE MEDICATIONS PAIN MANAGEMENT PRIOR TO AND DURING INFUSION: Five days prior to the first infusion of naxitamab in each cycle, initiate a 12-day course (Day -4 through Day 7) of prophylactic medication for neuropathic pain, such as gabapentin. Administer oral opioids 45 to 60 minutes prior to initiation of each naxitamab infusion and additional IV opioids as needed for breakthrough pain during the infusion. Consider the use of ketamine for pain that is not adequately controlled by opioids. PREMEDICATION: REDUCE RISK OF INFUSION-RELATED REACTIONS AND NAUSEA/VOMITING: Administer IV corticosteroids (e.g., methylprednisolone 2 mg/kg with maximum dose of 80 mg or equivalent corticosteroid dose) 30 minutes to 2 hours prior to the first infusion of naxitamab. Administer corticosteroid premedication for subsequent infusions if a severe infusion reaction occurred with the previous infusion or during the previous cycle. Administer an antihistamine, an H2 antagonist, acetaminophen and an antiemetic 30 minutes prior to each infusion. Refer to the GM-CSF Prescribing Information for recommended dosing information. Administer pre-infusion medications and supportive treatment, if needed, during infusion. Usual Pediatric Dose Neuroblastoma 1 year and older: 3 mg/kg/day (up to 150 mg/day) IV on Days 1, 3, and 5 of each cycle in combination with GM-CSF subcutaneously For the first infusion (Cycle 1, Day 1), administer over 60 minutes; for subsequent infusions, administer over 30 to 60 minutes, as tolerated. RECOMMENDED DOSE REGIMEN FOR EACH TREATMENT CYCLE: DAYS -4 to 0: Administer GM-CSF 250 mcg/m2 subcutaneously daily beginning 5 days prior to naxitamab infusion DAYS 1 to 5: Administer GM-CSF 500 mcg/m2 subcutaneously daily at least 1 hour prior to naxitamab on Days 1, 3, and 5 DAYS 1, 3, and 5: Administer naxitamab 3 mg/kg/day (up to 150 mg/day) IV Duration of therapy: Cycles are repeated every 4 weeks until complete response or partial response, followed by 5 additional cycles every 4 weeks. Subsequent cycles may be repeated every 8 weeks. Discontinue this drug and GM-CSF for disease progression or unacceptable toxicity. PREMEDICATIONS AND SUPPORTIVE MEDICATIONS PAIN MANAGEMENT PRIOR TO AND DURING INFUSION: Five days prior to the first infusion of naxitamab in each cycle, initiate a 12-day course (Day -4 through Day 7) of prophylactic medication for neuropathic pain, such as gabapentin. Administer oral opioids 45 to 60 minutes prior to initiation of each naxitamab infusion and additional IV opioids as needed for breakthrough pain during the infusion. Consider use of ketamine for pain that is not adequately controlled by opioids. PREMEDICATION: REDUCE RISK OF INFUSION-RELATED REACTIONS AND NAUSEA/VOMITING: Administer IV corticosteroids (e.g., methylprednisolone 2 mg/kg with maximum dose of 80 mg or equivalent corticosteroid dose) 30 minutes to 2 hours prior to the first infusion of naxitamab. Administer corticosteroid premedication for subsequent infusions if a severe infusion reaction occurred with the previous infusion or during the previous cycle. Administer an antihistamine, an H2 antagonist, acetaminophen and an antiemetic 30 minutes prior to each infusion. Refer to the GM-CSF Prescribing Information for recommended dosing information. Administer pre-infusion medications and supportive treatment, if needed, during infusion. Dose Adjustments MISSED DOSE: If a naxitamab dose is missed, administer the missed dose the following week by Day 10. Administer GM-CSF 500 mcg /m2 /day on the first day of the naxitamab infusion, and on the day before and on the day of the second and third infusion, respectively (i.e., a total of 5 days with 500 mcg /m2 /day). DOSE MODIFICATIONS FOR ADVERSE REACTIONS: INFUSION-RELATED REACTIONS: GRADE 2 (therapy or infusion interruption indicated but responds promptly to symptomatic treatment [e.g., antihistamines, NSAIDS, narcotics, IV fluids]; prophylactic medications indicated for 24 hours or less): Reduce naxitamab infusion rate to 50% of previous rate and monitor closely until recovery to Grade 1 or less; increase infusion rate gradually to rate prior to the event as tolerated. GRADE 3 (prolonged [e.g., not rapidly responsive to symptomatic medication and/or brief interruption of infusion]; recurrence of symptoms following initial improvement; hospitalization indicated for clinical sequelae): Immediately interrupt naxitamab infusion and monitor until recovery to Grade 2 or less; resume infusion at 50% of the rate prior to the event and increase infusion rate gradually to infusion rate prior to the event as tolerated; permanently discontinue therapy in patients not responding to medical intervention. GRADE 4 (e.g., life-threatening consequences: urgent intervention indicated or Grade 3 or 4 anaphylaxis): Permanently discontinue therapy. PAIN: GRADE 3 (e.g., unresponsive to maximum supportive measures): Permanently discontinue therapy. REVERSIBLE POSTERIOR LEUKOENCEPHALOPATHY SYNDROME (RPLS): ALL GRADES: Permanently discontinue therapy. TRANSVERSE MYELITIS: ALL GRADES: Permanently discontinue therapy. PERIPHERAL NEUROPATHY: Motor neuropathy (GRADE 2 or greater OR sensory neuropathy (GRADE 3 or 4): Permanently discontinue therapy. NEUROLOGICAL DISORDERS OF THE EYE: GRADE 2 to 4 resulting in decreased visual acuity or limiting activities of daily living: Withhold therapy until resolution; if resolved resume therapy at 50% of the prior dose; if tolerated without recurrence of symptoms, gradually increase to dose prior to onset of symptoms; permanently discontinue naxitamab if not resolved within 2 weeks or upon recurrence. Subtotal or total vision loss: Permanently discontinue therapy. PROLONGED URINARY RETENTION: Persisting following discontinuation of opioids: Permanently discontinue therapy. HYPERTENSION: GRADE 3: Withhold therapy or pause infusion until recovery to Grade 2 or less; resume infusion at 50% of prior rate; if tolerated without recurrence of symptoms, gradually increase to rate prior to onset of symptoms; permanently discontinue therapy in patients not responding to medical intervention. GRADE 4: Permanently discontinue therapy. OTHER ADVERSE REACTIONS: GRADE 3: Withhold therapy or pause infusion until recovery to Grade 2 or less; If resolved to Grade 2 or less resume at same rate; permanently discontinue therapy if not resolved to Grade 2 or less within 2 weeks. GRADE 4: Permanently discontinue therapy. Administration advice: Administer this drug as a diluted IV infusion. Do not administer as an IV push or bolus. Observe patients for a minimum of 2 hours following each infusion. Side Effects The Most Common vomiting nausea diarrhea loss of appetite anxiety tiredness cough, runny nose, fever, or other signs of infection severe headache, racing or irregular heartbeat, chest pain, dizziness, shortness of breath, nose bleeds, or fatigue severe pain anywhere in your body; numbness, tingling, or burning pain in your hands or feet; severe headache, confusion, thinking problems, weakness, and vision loss; a seizure; painful or difficult urination; cold symptoms–such as runny or stuffy nose, sneezing, sore throat, cough, low fever, and not feeling well; eye problems–blurred vision, trouble focusing, dilated pupils, unequal pupil size, being more sensitive to light; high blood pressure–headache, nausea, vomiting, dizziness, vision changes, nosebleeds, chest pain, fast or pounding heartbeats, pounding in your neck or ears; or low blood cell counts, or other abnormal lab tests; skin rash or hives; swelling; headache, fever, feeling tired; fast heart rate; feeling anxious or irritable; cough; or pain, bruising, swelling, or irritation where the medicine was injected.low blood cell counts–fever, chills, tiredness, mouth sores, skin sores, easy bruising, unusual bleeding, pale skin, cold hands and feet, feeling light-headed or short of breath. More common Back pain, sudden and severe bigger, dilated, or enlarged pupils (black part of eye) blurred vision bone pain burning, numbness, tingling, or painful sensations change in color vision chest tightness confusion decrease in frequency of urination decrease in urine volume difficulty in passing urine difficulty seeing at night dizziness drowsiness fever flushing headache increased sensitivity of the eyes to light muscle weakness, sudden and progressing nausea and vomiting nervousness painful urination pounding in the ears seizures slow or fast heartbeat stomach pain swelling trouble breathing unsteadiness or awkwardness unusual tiredness or weakness weakness in the arms, hands, legs, or feet Rare Constipation diarrhea Blistering, peeling, loosening of the skin chills cough decreased appetite fast heartbeat flushing, redness of the skin increased sweating itching joint or muscle pain red, irritated eyes runny nose sore throat sores, ulcers, or white spots in the mouth or on the lips unusual drowsiness, dullness, tiredness, weakness or feeling of sluggishness unusually warm skin Naxitamab-gqgk may cause other side effects. Call your doctor if you have any unusual problems while receiving this medication. If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration’s (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088). Drug interaction DRUG INTERACTION Acebutolol Naxitamab may decrease the antihypertensive activities of Acebutolol. Aceclofenac The risk or severity of hypertension can be increased when Aceclofenac is combined with Naxitamab. Acemetacin The risk or severity of hypertension can be increased when Acemetacin is combined with Naxitamab. Acetophenazine Acetophenazine may increase the neurotoxic activities of Naxitamab. Acetylsalicylic acid The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Naxitamab. Alclofenac The risk or severity of hypertension can be increased when Alclofenac is combined with Naxitamab. Alfentanil The risk or severity of hypertension can be increased when Alfentanil is combined with Naxitamab. Alimemazine Alimemazine may increase the neurotoxic activities of Naxitamab. Aliskiren Naxitamab may decrease the antihypertensive activities of Aliskiren. Almotriptan The risk or severity of hypertension can be increased when Almotriptan is combined with Naxitamab. Ambrisentan Naxitamab may decrease the antihypertensive activities of Ambrisentan. Aminophenazone The risk or severity of hypertension can be increased when Aminophenazone is combined with Naxitamab. Amisulpride Amisulpride may increase the neurotoxic activities of Naxitamab. Amitriptyline The risk or severity of hypertension can be increased when Amitriptyline is combined with Naxitamab. Amitriptylinoxide The risk or severity of hypertension can be increased when Amitriptylinoxide is combined with Naxitamab. Amlodipine Naxitamab may decrease the antihypertensive activities of Amlodipine. Amoxapine The risk or severity of hypertension can be increased when Amoxapine is combined with Naxitamab. Amphetamine The risk or severity of hypertension can be increased when Amphetamine is combined with Naxitamab. Antipyrine The risk or severity of hypertension can be increased when Antipyrine is combined with Naxitamab. Antrafenine The risk or severity of hypertension can be increased when Antrafenine is combined with Naxitamab. Arbutamine The risk or severity of hypertension can be increased when Arbutamine is combined with Naxitamab. Arformoterol The risk or severity of hypertension can be increased when Arformoterol is combined with Naxitamab. Aripiprazole The risk or severity of hypertension can be increased when Aripiprazole is combined with Naxitamab. Aripiprazole lauroxil The risk or severity of hypertension can be increased when Aripiprazole lauroxil is combined with Naxitamab. Asenapine The risk or severity of hypertension can be increased when Asenapine is combined with Naxitamab. Atenolol Naxitamab may decrease the antihypertensive activities of Atenolol. Atomoxetine The risk or severity of hypertension can be increased when Atomoxetine is combined with Naxitamab. Atropine The risk or severity of hypertension can be increased when Atropine is combined with Naxitamab. Azilsartan medoxomil Naxitamab may decrease the antihypertensive activities of Azilsartan medoxomil. Balsalazide The risk or severity of hypertension can be increased when Balsalazide is combined with Naxitamab. Benazepril Naxitamab may decrease the antihypertensive activities of Benazepril. Bendroflumethiazide Naxitamab may decrease the antihypertensive activities of Bendroflumethiazide. Benorilate The risk or severity of hypertension can be increased when Benorilate is combined with Naxitamab. Benoxaprofen The risk or severity of hypertension can be increased when Benoxaprofen is combined with Naxitamab. Benperidol Benperidol may increase the neurotoxic activities of Naxitamab. Benzphetamine The risk or severity of hypertension can be increased when Benzphetamine is combined with Naxitamab. Benzydamine The risk or severity of hypertension can be increased when Benzydamine is combined with Naxitamab. Bepridil Naxitamab may decrease the antihypertensive activities of Bepridil. Betaxolol Naxitamab may decrease the antihypertensive activities of Betaxolol. Bethanidine Naxitamab may decrease the antihypertensive activities of Bethanidine. Bismuth Bismuth subcitrate potassium may increase the neurotoxic activities of Naxitamab. Bismuth subgallate Bismuth subgallate may increase the neurotoxic activities of Naxitamab. Bismuth subnitrate Bismuth subnitrate may increase the neurotoxic activities of Naxitamab. Bisoprolol Naxitamab may decrease the antihypertensive activities of Bisoprolol. Bosentan Naxitamab may decrease the antihypertensive activities of Bosentan. Bretylium Naxitamab may decrease the antihypertensive activities of Bretylium. Brexpiprazole The risk or severity of hypertension can be increased when Brexpiprazole is combined with Naxitamab. Bromocriptine The risk or severity of hypertension can be increased when Bromocriptine is combined with Naxitamab. Bromperidol Bromperidol may increase the neurotoxic activities of Naxitamab. Bumadizone The risk or severity of hypertension can be increased when Bumadizone is combined with Naxitamab. Buspirone The risk or severity of hypertension can be increased when Buspirone is combined with Naxitamab. Butaperazine Butaperazine may increase the neurotoxic activities of Naxitamab. Butriptyline The risk or severity of hypertension can be increased when Butriptyline is combined with Naxitamab. Cabergoline The risk or severity of hypertension can be increased when Cabergoline is combined with Naxitamab. Candesartan Naxitamab may decrease the antihypertensive activities of Candesartan cilexetil. Cannabidiol The risk or severity of hypertension can be increased when Cannabidiol is combined with Naxitamab. Captopril Naxitamab may decrease the antihypertensive activities of Captopril. Cariprazine The risk or severity of hypertension can be increased when Cariprazine is combined with Naxitamab. Carprofen The risk or severity of hypertension can be increased when Carprofen is combined with Naxitamab. Carvedilol Naxitamab may decrease the antihypertensive activities of Carvedilol. Celecoxib The risk or severity of hypertension can be increased when Celecoxib is combined with Naxitamab. Celiprolol Naxitamab may decrease the antihypertensive activities of Celiprolol. Chlorothiazide Naxitamab may decrease the antihypertensive activities of Chlorothiazide. Chlorpromazine The risk or severity of hypertension can be increased when Chlorpromazine is combined with Naxitamab. Chlorprothixene Chlorprothixene may increase the neurotoxic activities of Naxitamab. Chlorthalidone Naxitamab may decrease the antihypertensive activities of Chlorthalidone. Choline The risk or severity of hypertension can be increased when Choline magnesium trisalicylate is combined with Naxitamab. Cilazapril Naxitamab may decrease the antihypertensive activities of Cilazapril. Clenbuterol The risk or severity of hypertension can be increased when Clenbuterol is combined with Naxitamab. Clindamycin Clindamycin may increase the neurotoxic activities of Naxitamab. Clomipramine The risk or severity of hypertension can be increased when Clomipramine is combined with Naxitamab. Clonidine Naxitamab may decrease the antihypertensive activities of Clonidine. Clothiapine Clothiapine may increase the neurotoxic activities of Naxitamab. Clozapine The risk or severity of hypertension can be increased when Clozapine is combined with Naxitamab. Cryptenamine Naxitamab may decrease the antihypertensive activities of Cryptenamine. Cyclobenzaprine Cyclobenzaprine may increase the neurotoxic activities of Naxitamab. Cyclopenthiazide Naxitamab may decrease the antihypertensive activities of Cyclopenthiazide. Cyclophosphamide Cyclophosphamide may increase the neurotoxic activities of Naxitamab. Cycloserine Cycloserine may increase the neurotoxic activities of Naxitamab. Cyclosporine The risk or severity of hypertension can be increased when Cyclosporine is combined with Naxitamab. Cyclothiazide Naxitamab may decrease the antihypertensive activities of Cyclothiazide. Dasiglucagon Naxitamab may decrease the antihypertensive activities of Dasiglucagon. Debrisoquine Naxitamab may decrease the antihypertensive activities of Debrisoquine. Decamethonium Decamethonium may increase the neurotoxic activities of Naxitamab. Deserpidine Naxitamab may decrease the antihypertensive activities of Deserpidine. Desflurane The risk or severity of hypertension can be increased when Desflurane is combined with Naxitamab. Desipramine The risk or severity of hypertension can be increased when Desipramine is combined with Naxitamab. Desmopressin The risk or severity of hypertension can be increased when Desmopressin is combined with Naxitamab. Dexibuprofen The risk or severity of hypertension can be increased when Dexibuprofen is combined with Naxitamab. Dexketoprofen The risk or severity of hypertension can be increased when Dexketoprofen is combined with Naxitamab. Dexmedetomidine The risk or severity of hypertension can be increased when Dexmedetomidine is combined with Naxitamab. Dexmethylphenidate The risk or severity of hypertension can be increased when Dexmethylphenidate is combined with Naxitamab. Dextroamphetamine The risk or severity of hypertension can be increased when Dextroamphetamine is combined with Naxitamab. Diazoxide Naxitamab may decrease the antihypertensive activities of Diazoxide. Dibenzepin The risk or severity of hypertension can be increased when Dibenzepin is combined with Naxitamab. Diclofenac The risk or severity of hypertension can be increased when Diclofenac is combined with Naxitamab. Didanosine Didanosine may increase the neurotoxic activities of Naxitamab. Diethylpropion The risk or severity of hypertension can be increased when Diethylpropion is combined with Naxitamab. Diflunisal The risk or severity of hypertension can be increased when Diflunisal is combined with Naxitamab. Dihydralazine Naxitamab may decrease the antihypertensive activities of Dihydralazine. Dihydroergocornine The risk or severity of hypertension can be increased when Dihydroergocornine is combined with Naxitamab. Dihydroergocristine The risk or severity of hypertension can be increased when Dihydroergocristine is combined with Naxitamab. Dihydroergotamine The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Naxitamab. Diltiazem Naxitamab may decrease the antihypertensive activities of Diltiazem. DMethylephedrine The risk or severity of hypertension can be increased when DL-Methylephedrine is combined with Naxitamab. Dobutamine The risk or severity of hypertension can be increased when Dobutamine is combined with Naxitamab. Dopamine The risk or severity of hypertension can be increased when Dopamine is combined with Naxitamab. Dopexamine The risk or severity of hypertension can be increased when Dopexamine is combined with Naxitamab. Dosulepin The risk or severity of hypertension can be increased when Dosulepin is combined with Naxitamab. Doxapram The risk or severity of hypertension can be increased when Doxapram is combined with Naxitamab. Doxazosin Naxitamab may decrease the antihypertensive activities of Doxazosin. Doxepin The risk or severity of hypertension can be increased when Doxepin is combined with Naxitamab. Dronedarone The risk or severity of hypertension can be increased when Dronedarone is combined with Naxitamab. Droperidol The risk or severity of hypertension can be increased when Droperidol is combined with Naxitamab. Droxidopa The risk or severity of hypertension can be increased when Droxidopa is combined with Naxitamab. Dutasteride The risk or severity of hypertension can be increased when Dutasteride is combined with Naxitamab. Eletriptan The risk or severity of hypertension can be increased when Eletriptan is combined with Naxitamab. Enalapril Naxitamab may decrease the antihypertensive activities of Enalapril. Enalaprilat Naxitamab may decrease the antihypertensive activities of Enalaprilat. Ephedrine The risk or severity of hypertension can be increased when Ephedrine is combined with Naxitamab. Epinephrine The risk or severity of hypertension can be increased when Epinephrine is combined with Naxitamab. Eplerenone Naxitamab may decrease the antihypertensive activities of Eplerenone. Epoprostenol Naxitamab may decrease the antihypertensive activities of Epoprostenol. Eprosartan Naxitamab may decrease the antihypertensive activities of Eprosartan. Ergoloid mesylate The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Naxitamab. Ergometrine The risk or severity of hypertension can be increased when Ergometrine is combined with Naxitamab. Ergotamine The risk or severity of hypertension can be increased when Ergotamine is combined with Naxitamab. Esketamine The risk or severity of hypertension can be increased when Esketamine is combined with Naxitamab. Esmolol Naxitamab may decrease the antihypertensive activities of Esmolol. Etafedrine The risk or severity of hypertension can be increased when Etafedrine is combined with Naxitamab. Ethanol Ethanol may increase the neurotoxic activities of Naxitamab. Etilefrine The risk or severity of hypertension can be increased when Etilefrine is combined with Naxitamab. Etodolac The risk or severity of hypertension can be increased when Etodolac is combined with Naxitamab. Etomidate The risk or severity of hypertension can be increased when Etomidate is combined with Naxitamab. Etoricoxib The risk or severity of hypertension can be increased when Etoricoxib is combined with Naxitamab. Felodipine Naxitamab may decrease the antihypertensive activities of Felodipine. Fenbufen The risk or severity of hypertension can be increased when Fenbufen is combined with Naxitamab. Fenoldopam Naxitamab may decrease the antihypertensive activities of Fenoldopam. Fenoprofen The risk or severity of hypertension can be increased when Fenoprofen is combined with Naxitamab. Fenoterol The risk or severity of hypertension can be increased when Fenoterol is combined with Naxitamab. Fentanyl The risk or severity of hypertension can be increased when Fentanyl is combined with Naxitamab. Finasteride The risk or severity of hypertension can be increased when Finasteride is combined with Naxitamab. Flibanserin The risk or severity of hypertension can be increased when Flibanserin is combined with Naxitamab. Floctafenine The risk or severity of hypertension can be increased when Floctafenine is combined with Naxitamab. Flupentixol The risk or severity of hypertension can be increased when Flupentixol is combined with Naxitamab. Fluphenazine Fluphenazine may increase the neurotoxic activities of Naxitamab. Flurbiprofen The risk or severity of hypertension can be increased when Flurbiprofen is combined with Naxitamab. Fluspirilene Fluspirilene may increase the neurotoxic activities of Naxitamab. Formoterol The risk or severity of hypertension can be increased when Formoterol is combined with Naxitamab. Fosinopril Naxitamab may decrease the antihypertensive activities of Fosinopril. Frovatriptan The risk or severity of hypertension can be increased when Frovatriptan is combined with Naxitamab. Furosemide Naxitamab may decrease the antihypertensive activities of Furosemide. Guanabenz Naxitamab may decrease the antihypertensive activities of Guanabenz. Guanadrel Naxitamab may decrease the antihypertensive activities of Guanadrel. Guanethidine Naxitamab may decrease the antihypertensive activities of Guanethidine. Guanfacine Naxitamab may decrease the antihypertensive activities of Guanfacine. Guanoxan Naxitamab may decrease the antihypertensive activities of Guanoxan. Haloperidol Haloperidol may increase the neurotoxic activities of Naxitamab. Halothane The risk or severity of hypertension can be increased when Halothane is combined with Naxitamab. Hydralazine Naxitamab may decrease the antihypertensive activities of Hydralazine. Hydrochlorothiazide Naxitamab may decrease the antihypertensive activities of Hydrochlorothiazide. Hydroflumethiazide Naxitamab may decrease the antihypertensive activities of Hydroflumethiazide. Ibuprofen The risk or severity of hypertension can be increased when Ibuprofen is combined with Naxitamab. Icosapent The risk or severity of hypertension can be increased when Icosapent is combined with Naxitamab. Iloperidone The risk or severity of hypertension can be increased when Iloperidone is combined with Naxitamab. Imipenem Imipenem may increase the neurotoxic activities of Naxitamab. Imipramine The risk or severity of hypertension can be increased when Imipramine is combined with Naxitamab. Indacaterol The risk or severity of hypertension can be increased when Indacaterol is combined with Naxitamab. Indapamide Naxitamab may decrease the antihypertensive activities of Indapamide. Indomethacin The risk or severity of hypertension can be increased when Indomethacin is combined with Naxitamab. Indoramin Naxitamab may decrease the antihypertensive activities of Indoramin. Iofetamine I-123 The risk or severity of hypertension can be increased when Iofetamine I-123 is combined with Naxitamab. Irbesartan Naxitamab may decrease the antihypertensive activities of Irbesartan. Isocarboxazid The risk or severity of hypertension can be increased when Isocarboxazid is combined with Naxitamab. Isoetharine The risk or severity of hypertension can be increased when Isoetharine is combined with Naxitamab. Isoflurane The risk or severity of hypertension can be increased when Isoflurane is combined with Naxitamab. Isometheptene The risk or severity of hypertension can be increased when Isometheptene is combined with Naxitamab. Isoprenaline The risk or severity of hypertension can be increased when Isoprenaline is combined with Naxitamab. Isoxicam The risk or severity of hypertension can be increased when Isoxicam is combined with Naxitamab. Isoxsuprine The risk or severity of hypertension can be increased when Isoxsuprine is combined with Naxitamab. Isradipine Naxitamab may decrease the antihypertensive activities of Isradipine. Ketoprofen The risk or severity of hypertension can be increased when Ketoprofen is combined with Naxitamab. Ketorolac The risk or severity of hypertension can be increased when Ketorolac is combined with Naxitamab. Labetalol Naxitamab may decrease the antihypertensive activities of Labetalol. Lacidipine Naxitamab may decrease the antihypertensive activities of Lacidipine. Lercanidipine Naxitamab may decrease the antihypertensive activities of Lercanidipine. Levamlodipine Naxitamab may decrease the antihypertensive activities of Levamlodipine. Levonordefrin The risk or severity of hypertension can be increased when Levonordefrin is combined with Naxitamab. Levosalbutamol The risk or severity of hypertension can be increased when Levosalbutamol is combined with Naxitamab. Lincomycin Lincomycin may increase the neurotoxic activities of Naxitamab. Linezolid The risk or severity of hypertension can be increased when Linezolid is combined with Naxitamab. Lisdexamfetamine The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Naxitamab. Lisinopril Naxitamab may decrease the antihypertensive activities of Lisinopril. Lisuride The risk or severity of hypertension can be increased when Lisuride is combined with Naxitamab. Lofexidine Naxitamab may decrease the antihypertensive activities of Lofexidine. Lornoxicam The risk or severity of hypertension can be increased when Lornoxicam is combined with Naxitamab. Losartan Naxitamab may decrease the antihypertensive activities of Losartan. Loxapine Loxapine may increase the neurotoxic activities of Naxitamab. Loxoprofen The risk or severity of hypertension can be increased when Loxoprofen is combined with Naxitamab. Lumiracoxib The risk or severity of hypertension can be increased when Lumiracoxib is combined with Naxitamab. Lurasidone The risk or severity of hypertension can be increased when Lurasidone is combined with Naxitamab. Macitentan Naxitamab may decrease the antihypertensive activities of Macitentan. Manidipine Naxitamab may decrease the antihypertensive activities of Manidipine. Mecamylamine Naxitamab may decrease the antihypertensive activities of Mecamylamine. Meclofenamic acid The risk or severity of hypertension can be increased when Meclofenamic acid is combined with Naxitamab. Mefenamic acid The risk or severity of hypertension can be increased when Mefenamic acid is combined with Naxitamab. Meloxicam The risk or severity of hypertension can be increased when Meloxicam is combined with Naxitamab. Mephentermine The risk or severity of hypertension can be increased when Mephentermine is combined with Naxitamab. Mesalazine The risk or severity of hypertension can be increased when Mesalazine is combined with Naxitamab. Mesoridazine Mesoridazine may increase the neurotoxic activities of Naxitamab. Metamfetamine The risk or severity of hypertension can be increased when Metamfetamine is combined with Naxitamab. Metamizole The risk or severity of hypertension can be increased when Metamizole is combined with Naxitamab. Metaraminol The risk or severity of hypertension can be increased when Metaraminol is combined with Naxitamab. Metergoline The risk or severity of hypertension can be increased when Metergoline is combined with Naxitamab. Methotrimeprazine The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Naxitamab. Methoxamine The risk or severity of hypertension can be increased when Methoxamine is combined with Naxitamab. Methoxyflurane The risk or severity of hypertension can be increased when Methoxyflurane is combined with Naxitamab. Methoxyphenamine The risk or severity of hypertension can be increased when Methoxyphenamine is combined with Naxitamab. Methyldopa Naxitamab may decrease the antihypertensive activities of Methyldopa. Methylene blue The risk or severity of hypertension can be increased when Methylene blue is combined with Naxitamab. Methylergometrine The risk or severity of hypertension can be increased when Methylergometrine is combined with Naxitamab. Methylphenidate The risk or severity of hypertension can be increased when Methylphenidate is combined with Naxitamab. Methysergide The risk or severity of hypertension can be increased when Methysergide is combined with Naxitamab. Metolazone Naxitamab may decrease the antihypertensive activities of Metolazone. Metoprolol Naxitamab may decrease the antihypertensive activities of Metoprolol. Metyrosine Naxitamab may decrease the antihypertensive activities of Metyrosine. Mianserin The risk or severity of hypertension can be increased when Mianserin is combined with Naxitamab. Midodrine The risk or severity of hypertension can be increased when Midodrine is combined with Naxitamab. Minaprine The risk or severity of hypertension can be increased when Minaprine is combined with Naxitamab. Minoxidil Naxitamab may decrease the antihypertensive activities of Minoxidil. Mirabegron The risk or severity of hypertension can be increased when Mirabegron is combined with Naxitamab. Mirtazapine The risk or severity of hypertension can be increased when Mirtazapine is combined with Naxitamab. Moclobemide The risk or severity of hypertension can be increased when Moclobemide is combined with Naxitamab. Moexipril Naxitamab may decrease the antihypertensive activities of Moexipril. Molindone Molindone may increase the neurotoxic activities of Naxitamab. Moricizine Moricizine may increase the neurotoxic activities of Naxitamab. Moxisylyte The risk or severity of hypertension can be increased when Moxisylyte is combined with Naxitamab. Moxonidine Naxitamab may decrease the antihypertensive activities of Moxonidine. Muzolimine Naxitamab may decrease the antihypertensive activities of Muzolimine. Nabumetone The risk or severity of hypertension can be increased when Nabumetone is combined with Naxitamab. Nadolol Naxitamab may decrease the antihypertensive activities of Nadolol. Naphazoline The risk or severity of hypertension can be increased when Naphazoline is combined with Naxitamab. Naproxen The risk or severity of hypertension can be increased when Naproxen is combined with Naxitamab. Naratriptan The risk or severity of hypertension can be increased when Naratriptan is combined with Naxitamab. Nebivolol Naxitamab may decrease the antihypertensive activities of Nebivolol. Nefazodone The risk or severity of hypertension can be increased when Nefazodone is combined with Naxitamab. Neomycin Neomycin may increase the neurotoxic activities of Naxitamab. Nialamide The risk or severity of hypertension can be increased when Nialamide is combined with Naxitamab. Nicardipine Naxitamab may decrease the antihypertensive activities of Nicardipine. Nicergoline The risk or severity of hypertension can be increased when Nicergoline is combined with Naxitamab. Nicorandil Naxitamab may decrease the antihypertensive activities of Nicorandil. Nilvadipine Naxitamab may decrease the antihypertensive activities of Nilvadipine. Nimesulide The risk or severity of hypertension can be increased when Nimesulide is combined with Naxitamab. Nimodipine Naxitamab may decrease the antihypertensive activities of Nimodipine. Nisoldipine Naxitamab may decrease the antihypertensive activities of Nisoldipine. Nitrendipine Naxitamab may decrease the antihypertensive activities of Nitrendipine. Nitroglycerin Naxitamab may decrease the antihypertensive activities of Nitroglycerin. Nitroprusside Naxitamab may decrease the antihypertensive activities of Nitroprusside. Nitrous oxide The risk or severity of hypertension can be increased when Nitrous oxide is combined with Naxitamab. Norepinephrine The risk or severity of hypertension can be increased when Norepinephrine is combined with Naxitamab. Nortriptyline The risk or severity of hypertension can be increased when Nortriptyline is combined with Naxitamab. Nylidrin The risk or severity of hypertension can be increased when Nylidrin is combined with Naxitamab. Olmesartan Naxitamab may decrease the antihypertensive activities of Olmesartan. Olodaterol The risk or severity of hypertension can be increased when Olodaterol is combined with Naxitamab. Olsalazine The risk or severity of hypertension can be increased when Olsalazine is combined with Naxitamab. Orciprenaline The risk or severity of hypertension can be increased when Orciprenaline is combined with Naxitamab. Oxaprozin The risk or severity of hypertension can be increased when Oxaprozin is combined with Naxitamab. Oxprenolol Naxitamab may decrease the antihypertensive activities of Oxprenolol. Oxymetazoline The risk or severity of hypertension can be increased when Oxymetazoline is combined with Naxitamab. Oxyphenbutazone The risk or severity of hypertension can be increased when Oxyphenbutazone is combined with Naxitamab. Paclitaxel Paclitaxel may increase the neurotoxic activities of Naxitamab. Paliperidone The risk or severity of hypertension can be increased when Paliperidone is combined with Naxitamab. Parecoxib The risk or severity of hypertension can be increased when Parecoxib is combined with Naxitamab. Pargyline Naxitamab may decrease the antihypertensive activities of Pargyline. Penbutolol Naxitamab may decrease the antihypertensive activities of Penbutolol. Pentolinium Naxitamab may decrease the antihypertensive activities of Pentolinium. Perazine Perazine may increase the neurotoxic activities of Naxitamab. Pergolide The risk or severity of hypertension can be increased when Pergolide is combined with Naxitamab. Periciazine The risk or severity of hypertension can be increased when Periciazine is combined with Naxitamab. Perindopril Naxitamab may decrease the antihypertensive activities of Perindopril. Perphenazine Perphenazine may increase the neurotoxic activities of Naxitamab. Phendimetrazine The risk or severity of hypertension can be increased when Phendimetrazine is combined with Naxitamab. Phenelzine The risk or severity of hypertension can be increased when Phenelzine is combined with Naxitamab. Phenmetrazine The risk or severity of hypertension can be increased when Phenmetrazine is combined with Naxitamab. Phenoxybenzamine Naxitamab may decrease the antihypertensive activities of Phenoxybenzamine. Phentermine The risk or severity of hypertension can be increased when Phentermine is combined with Naxitamab. Phentolamine Naxitamab may decrease the antihypertensive activities of Phentolamine. Phenylbutazone The risk or severity of hypertension can be increased when Phenylbutazone is combined with Naxitamab. Phenylephrine The risk or severity of hypertension can be increased when Phenylephrine is combined with Naxitamab. Phenylpropanolam The risk or severity of hypertension can be increased when Phenylpropanolamine is combined with Naxitamab. Pimavanserin Pimavanserin may increase the neurotoxic activities of Naxitamab. Pimozide Pimozide may increase the neurotoxic activities of Naxitamab. Pinacidil Naxitamab may decrease the antihypertensive activities of Pinacidil. Pindolol Naxitamab may decrease the antihypertensive activities of Pindolol. Pipotiazine Pipotiazine may increase the neurotoxic activities of Naxitamab. Pirbuterol The risk or severity of hypertension can be increased when Pirbuterol is combined with Naxitamab. Piroxicam The risk or severity of hypertension can be increased when Piroxicam is combined with Naxitamab. Pizotifen The risk or severity of hypertension can be increased when Pizotifen is combined with Naxitamab. Polymyxin B Polymyxin B may increase the neurotoxic activities of Naxitamab. Polythiazide Naxitamab may decrease the antihypertensive activities of Polythiazide. Practolol Naxitamab may decrease the antihypertensive activities of Practolol. Prazosin Naxitamab may decrease the antihypertensive activities of Prazosin. Procaterol The risk or severity of hypertension can be increased when Procaterol is combined with Naxitamab. Prochlorperazine Prochlorperazine may increase the neurotoxic activities of Naxitamab. Promazine The risk or severity of hypertension can be increased when Promazine is combined with Naxitamab. Promethazine Promethazine may increase the neurotoxic activities of Naxitamab. Propafenone The risk or severity of hypertension can be increased when Propafenone is combined with Naxitamab. Propiomazine The risk or severity of hypertension can be increased when Propiomazine is combined with Naxitamab. Propiverine The risk or severity of hypertension can be increased when Propiverine is combined with Naxitamab. Propofol The risk or severity of hypertension can be increased when Propofol is combined with Naxitamab. Propranolol Naxitamab may decrease the antihypertensive activities of Propranolol. Protriptyline The risk or severity of hypertension can be increased when Protriptyline is combined with Naxitamab. Pseudoephedrine The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Naxitamab. Quetiapine The risk or severity of hypertension can be increased when Quetiapine is combined with Naxitamab. Quinapril Naxitamab may decrease the antihypertensive activities of Quinapril. Quinidine The risk or severity of hypertension can be increased when Quinidine is combined with Naxitamab. Quinupramine The risk or severity of hypertension can be increased when Quinupramine is combined with Naxitamab. Racepinephrine The risk or severity of hypertension can be increased when Racepinephrine is combined with Naxitamab. Ramipril Naxitamab may decrease the antihypertensive activities of Ramipril. Rasagiline The risk or severity of hypertension can be increased when Rasagiline is combined with Naxitamab. Remifentanil The risk or severity of hypertension can be increased when Remifentanil is combined with Naxitamab. Remoxipride Remoxipride may increase the neurotoxic activities of Naxitamab. Rescinnamine Naxitamab may decrease the antihypertensive activities of Rescinnamine. Reserpine Naxitamab may decrease the antihypertensive activities of Reserpine. Rilmenidine Naxitamab may decrease the antihypertensive activities of Rilmenidine. Riociguat Naxitamab may decrease the antihypertensive activities of Riociguat. Risperidone The risk or severity of hypertension can be increased when Risperidone is combined with Naxitamab. Ritodrine The risk or severity of hypertension can be increased when Ritodrine is combined with Naxitamab. Rizatriptan The risk or severity of hypertension can be increased when Rizatriptan is combined with Naxitamab. Rofecoxib The risk or severity of hypertension can be increased when Rofecoxib is combined with Naxitamab. Rotigotine The risk or severity of hypertension can be increased when Rotigotine is combined with Naxitamab. Safinamide The risk or severity of hypertension can be increased when Safinamide is combined with Naxitamab. Salbutamol The risk or severity of hypertension can be increased when Salbutamol is combined with Naxitamab. Salicylamide The risk or severity of hypertension can be increased when Salicylamide is combined with Naxitamab. Salicylic acid The risk or severity of hypertension can be increased when Salicylic acid is combined with Naxitamab. Salmeterol The risk or severity of hypertension can be increased when Salmeterol is combined with Naxitamab. Salsalate The risk or severity of hypertension can be increased when Salsalate is combined with Naxitamab. Selegiline The risk or severity of hypertension can be increased when Selegiline is combined with Naxitamab. Selexipag Naxitamab may decrease the antihypertensive activities of Selexipag. Selpercatinib The risk or severity of hypertension can be increased when Selpercatinib is combined with Naxitamab. Serdexmethyl The risk or severity of hypertension can be increased when Naxitamab is combined with Serdexmethylphenidate. Sertindole Sertindole may increase the neurotoxic activities of Naxitamab. Sevoflurane The risk or severity of hypertension can be increased when Sevoflurane is combined with Naxitamab. Siponimod The risk or severity of hypertension can be increased when Siponimod is combined with Naxitamab. Sitaxentan Naxitamab may decrease the antihypertensive activities of Sitaxentan. Sodium citrate Sodium citrate may increase the neurotoxic activities of Naxitamab. Solifenacin The risk or severity of hypertension can be increased when Solifenacin is combined with Naxitamab. Solriamfetol The risk or severity of hypertension can be increased when Solriamfetol is combined with Naxitamab. Spirapril Naxitamab may decrease the antihypertensive activities of Spirapril. Stavudine Stavudine may increase the neurotoxic activities of Naxitamab. Succinylcholine Succinylcholine may increase the neurotoxic activities of Naxitamab. Sufentanil The risk or severity of hypertension can be increased when Sufentanil is combined with Naxitamab. Sulfasalazine The risk or severity of hypertension can be increased when Sulfasalazine is combined with Naxitamab. Sulindac The risk or severity of hypertension can be increased when Sulindac is combined with Naxitamab. Sulpiride Sulpiride may increase the neurotoxic activities of Naxitamab. Sultopride Sultopride may increase the neurotoxic activities of Naxitamab. Sumatriptan The risk or severity of hypertension can be increased when Sumatriptan is combined with Naxitamab. Tadalafil Naxitamab may decrease the antihypertensive activities of Tadalafil. Telmisartan Naxitamab may decrease the antihypertensive activities of Telmisartan. Teniposide Teniposide may increase the neurotoxic activities of Naxitamab. Tenoxicam The risk or severity of hypertension can be increased when Tenoxicam is combined with Naxitamab. Terazosin Naxitamab may decrease the antihypertensive activities of Terazosin. Terbutaline The risk or severity of hypertension can be increased when Terbutaline is combined with Naxitamab. Testosterone Testosterone undecanoate may increase the hypertensive activities of Naxitamab. Tetryzoline The risk or severity of hypertension can be increased when Tetryzoline is combined with Naxitamab. Thiethylperazine Thiethylperazine may increase the neurotoxic activities of Naxitamab. Thioridazine The risk or severity of hypertension can be increased when Thioridazine is combined with Naxitamab. Thiothixene Thiothixene may increase the neurotoxic activities of Naxitamab. Tiaprofenic acid The risk or severity of hypertension can be increased when Tiaprofenic acid is combined with Naxitamab. Timolol Naxitamab may decrease the antihypertensive activities of Timolol. Tolazoline Naxitamab may decrease the antihypertensive activities of Tolazoline. Tolfenamic acid The risk or severity of hypertension can be increased when Tolfenamic acid is combined with Naxitamab. Tolmetin The risk or severity of hypertension can be increased when Tolmetin is combined with Naxitamab. Torasemide Naxitamab may decrease the antihypertensive activities of Torasemide. Trandolapril Naxitamab may decrease the antihypertensive activities of Trandolapril. Tranylcypromine The risk or severity of hypertension can be increased when Tranylcypromine is combined with Naxitamab. Trazodone The risk or severity of hypertension can be increased when Trazodone is combined with Naxitamab. Treprostinil Naxitamab may decrease the antihypertensive activities of Treprostinil. Trichlormethiazide Naxitamab may decrease the antihypertensive activities of Trichlormethiazide. Trichloroethylene The risk or severity of hypertension can be increased when Trichloroethylene is combined with Naxitamab. Trifluoperazine The risk or severity of hypertension can be increased when Trifluoperazine is combined with Naxitamab. Triflupromazine Triflupromazine may increase the neurotoxic activities of Naxitamab. Trimethaphan Naxitamab may decrease the antihypertensive activities of Trimethaphan. Trimipramine The risk or severity of hypertension can be increased when Trimipramine is combined with Naxitamab. Tubocurarine Tubocurarine may increase the neurotoxic activities of Naxitamab. Valdecoxib The risk or severity of hypertension can be increased when Valdecoxib is combined with Naxitamab. Valproate bismuth Valproate bismuth may increase the neurotoxic activities of Naxitamab. Valsartan Naxitamab may decrease the antihypertensive activities of Valsartan. Vilanterol The risk or severity of hypertension can be increased when Vilanterol is combined with Naxitamab. Vilazodone The risk or severity of hypertension can be increased when Vilazodone is combined with Naxitamab. Vincristine Vincristine may increase the neurotoxic activities of Naxitamab. Vinorelbine Vinorelbine may increase the neurotoxic activities of Naxitamab. Viomycin Viomycin may increase the neurotoxic activities of Naxitamab. Vortioxetine The risk or severity of hypertension can be increased when Vortioxetine is combined with Naxitamab. Xamoterol The risk or severity of hypertension can be increased when Xamoterol is combined with Naxitamab. Xylometazoline The risk or severity of hypertension can be increased when Xylometazoline is combined with Naxitamab. Yohimbine The risk or severity of hypertension can be increased when Yohimbine is combined with Naxitamab. Ziprasidone The risk or severity of hypertension can be increased when Ziprasidone is combined with Naxitamab. Zofenopril Naxitamab may decrease the antihypertensive activities of Zofenopril. Zolmitriptan The risk or severity of hypertension can be increased when Zolmitriptan is combined with Naxitamab. Pregnancy and Lactation US FDA pregnancy category: Not assigned. Pregnancy Based on its mechanism of action, Naxitamab-gqgk may cause fetal harm when administered to pregnant women. There are no available data on the use of Naxitamab-gqgk in pregnant women and no animal reproduction studies have been conducted with Naxitamab-gqgk. IgG1 monoclonal antibodies are transported across the placenta in a linear fashion as pregnancy progresses, with the largest amount transferred during the third trimester. Advise pregnant women of the potential risk to a fetus. Lactation There are no data on the presence of naxitamab-gqgk in human milk or its effects on the breastfed child, or on milk production, however, human IgG is present in human milk. Because of the potential for serious adverse reactions in a breastfed child from DANYELZA, advise women not to breastfeed during treatment and for 2 months after the final dose. How should this medicine be used? Naxitamab-gqgk comes as a solution (liquid) to be injected intravenously (into a vein) over 30 to 60 minutes by a doctor or nurse in a medical facility or infusion center. It is usually given on days 1, 3, and 5 of a 28-day treatment cycle and it may be repeated based on your response. After the initial treatment, your doctor may prescribe additional treatment cycles every 8 weeks. Your doctor will probably treat you with other medications before and during each dose to help prevent certain side effects. Your doctor may need to temporarily or permanently stop your treatment or decrease your dose of naxitamab-gqgk during your treatment. This depends on how well the medication works for you and the side effects you experience. Be sure to tell your doctor how you are feeling during your treatment with naxitamab-gqgk. What special precautions should I follow? Before receiving naxitamab-gqgk, tell your doctor and pharmacist if you are allergic to naxitamab-gqgk, any other medications, or any of the ingredients in naxitamab-gqgk injection. Ask your pharmacist or check the Medication Guide for a list of the ingredients. tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects. tell your doctor if you have or have ever had hypertension or urinary retention (sudden inability to urinate). tell your doctor if you are pregnant or plan to become pregnant. You must take a pregnancy test before starting treatment. You should use effective birth control during your treatment and for 2 months after your final dose. If you become pregnant while receiving naxitamab-gqgk, call your doctor. Naxitamab-gqgk may harm the fetus. tell your doctor if you are breastfeeding. You should not breastfeed during your treatment with naxitamab-gqgk and for 2 months after your final dose. References https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761171lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/761171Orig1s000ltr.pdf https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=29a80c6b-8bad-4650-8c7f-f18490c868ec https://druginfo.nlm.nih.gov/drugportal/name/Naxitamab https://www.drugs.com/mtm/naxitamab.html https://go.drugbank.com/drugs/DB15965 https://www.mayoclinic.org/drugs-supplements/naxitamab-gqgk-intravenous-route/side-effects/drg-20506347 https://medlineplus.gov/druginfo/meds/a621005.html https://en.wikipedia.org/wiki/Naxitamab https://www.webmd.com/drugs/2/drug-180455/naxitamab-gqgk-intravenous/details/list-contraindications Show More